J&J Duragesic Pediatric Exclusivity Keeps Mylan Fentanyl Patch Off The Market Until January
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA rejects Mylan's argument linking pediatric exclusivity with the 30-month stay. Mylan says it will sue FDA to restore final approval of its ANDA, which is now deemed tentatively approved.